Author Interviews, Biomarkers, Lancet, Lymphoma, NIH / 06.04.2015 Interview with: Dr. Mark Roschewski, MD and Dr Wyndham H Wilson MD-PhD Lymphoma Therapeutics Section Lymphoid Malignancies Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda, MD 20892 Medical Research: What is the background for this study? What are the main findings? Response: Monitoring patients with diffuse large B-cell lymphoma (DLBCL) has relied on computed tomography (CT) scans which are imprecise, expensive and include radiation. We investigated the ability of a blood-based assay to monitor patients with DLBCL during and after their initial therapy. The assay we studied amplifies and quantifies small amounts of circulating tumor DNA from the patient’s blood. We showed that this assay effectively predicts which patients will relapse and identifies recurrence 3.5 months before CT scans. (more…)
Author Interviews, Cancer Research, Lymphoma, NEJM / 22.11.2013

Kieron M. Dunleavy, M.D. Metabolism Branch Lymphoma Therapeutics Section Staff Clinician Center for Cancer Research National Cancer Institute Bethesda, MD Interview with Kieron M. Dunleavy, M.D. Metabolism Branch Lymphoma Therapeutics Section Center for Cancer Research National Cancer Institute, Bethesda, MD 20892 What are the main findings of the study? Dr. Dunleavy: We found that low-intensity therapy was highly effective in Burkitt's lymphoma and cured over 95% of patients with the disease. (more…)
Author Interviews, HIV, Infections, JNCI, Lymphoma / 08.08.2013 Interview with: Satish Gopal, MD, MPH Program in Global Oncology, Lineberger Comprehensive Cancer Center UNC Project-Malawi, Tidziwe Center, Private Bag A-104, Lilongwe, Malawi What is the primary message our physician readers should take away from the piece?” Answer: Lymphoma is one of the leading causes of HIV-associated death in the modern ART era. In our analyses of a large multicenter US cohort, survival for HIV-associated lymphoma patients receiving routine care has not clearly improved since the modern ART era began, and remains significantly worse than SEER outcomes for the same lymphoma subtypes in the general population. This was somewhat surprising in an era of normalizing life expectancy for HIV-infected patients on ART, and quite different from the outstanding results achieved for this population in recent clinical trials conducted by AMC and NCI. (more…)